Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients

NCT02690142 is registered in ClinicalTrials.gov with Affibody as lead sponsor.

NCT NCT02690142
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02690142 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Partially-randomised, Partially Double-blinded, Safety, Tolerability and Pharmacokinetic Study of ABY-035 in Healthy Subjects and Psoriasis Patients
Lead sponsor
Affibody
Phase
Phase 1
Overall status
Completed
Start date
February 29, 2016
Completion date
January 10, 2018
Enrollment
72 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects, psoriasis